언어 선택

CD37

CD37 분자 정보

영어 이름	Leukocyte antigen CD37	시판 약물 수	0
임상 약물 수	9	표적 별명	CD37，Tetraspanin-26，CD37 Molecule，CD37 Antigen，Tspan-26，TSPAN26，Cell Differentiation Antigen 37，Leukocyte Surface Antigen CD37，Leukocyte Antigen CD37，GP52-40
최고 연구 개발 단계	Phase 2 Clinical

영어 이름	Leukocyte antigen CD37
표적 별명	CD37，Tetraspanin-26，CD37 Molecule，CD37 Antigen，Tspan-26，TSPAN26，Cell Differentiation Antigen 37，Leukocyte Surface Antigen CD37，Leukocyte Antigen CD37，GP52-40
시판 약물 수	0
임상 약물 수	9
최고 연구 개발 단계	Phase 2 Clinical

CD37 제품 목록

속성
Protein (5)
제품 라이브러리
온라인 (5)
종
Human (5)
태그
Fc Tag (2)His Tag (1)- (2)
마커
Unconjugated (4)FITC Labeled (1)

제품 번호	종	발현 시스템	제품 설명
HOT CD7-H52D3	Human	HEK293	Human CD37 Full Length Protein, His,Flag Tag (Detergent)
HOT CD7-H52H3	Human	HEK293	Human CD37 Protein, His Tag
HOT CD7-H52P4	Human	HEK293	Human CD37 Full Length Protein (VLP)
CD7-H525a	Human	HEK293	Human CD37 Protein, Fc Tag (MALS verified)
CD7-HF26x	Human	HEK293	FITC-Labeled Human CD37 Protein, Fc Tag

총 수량5

CD37분자 배경

Leukocyte antigen CD37 (CD37) is also known as Tetraspanin-26 (Tspan-26) and TSPAN26,which is a member of the transmembrane 4 superfamily or tetraspanin family. Most of these members are cell-surface proteins that are characterized by the presence of four hydrophobic domains. The proteins encoded by CD37 gene mediate signal transduction events that play a role in the regulation of cell development, activation, growth and motility. CD37 is a cell surface glycoprotein that is known to complex with integrins and other transmembrane 4 superfamily proteins. CD37 may play a role in T-cell-B-cell interactions.

CD37분자 별명

CD37,Tspan-26,TSPAN26

라이선싱 협력

프로젝트 이름	약물 유형	치료 영역	적응증	단계	권리 지역
CD37+CD22 CAR-T	Cell therapy	Oncology/Cancer	AML	PCC	Global

임상 약물 정보

영어 이름	연구 코드	연구 개발 단계	회사	적응증	임상 시험
Lutetium (177lu) lilotomab satetraxetan	177Lu-DOTA-HH1	Phase 2 Clinical	Nordic Nanovector	Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin	상세
DS-3790a	DS3790a; DS-3790a	Phase 2 Clinical	Daiichi Sankyo Co Ltd	Hematologic Neoplasms	상세
Naratuximab emtansine	IMGN-529; K7153A-SMCC-DM1	Phase 2 Clinical	Immunogen Inc	Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin	상세
Debio-1562M	Debio-1562M	Phase 2 Clinical	Debiopharm International Sa	Leukemia, Myeloid, Acute; Neoplasms	상세
AGS-67E	AGS-67E	Phase 1 Clinical	Agensys Inc	Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin	상세
CAR-37 T cell therapy (Massachusetts General Hospital)		Phase 1 Clinical	Massachusetts General Hospital	Hematologic Neoplasms; Leukemia; Lymphoma; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell	상세
CAR-37 T cells(The General Hospital)		Phase 1 Clinical	The General Hospital Corporation D/B/A Massachusetts General Hospital	Hematologic Neoplasms; Leukemia; Lymphoma; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell	상세
anti-CD19 + anti-CD37 bispecific CAR T-cell therapy (Forevertek Biotechnology/Huazhong University of Science and Technology)		Clinical	Huazhong University Of Science And Technology	Lymphoma, Non-Hodgkin	상세
DS3790	DS-3790; DS3790	Clinical	Daiichi Sankyo Inc	Hematologic Neoplasms	상세